Theratechnologies IPO év
Mi az Theratechnologies IPO év?
A IPO év az Theratechnologies Inc. - 2009
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a Theratechnologies -hoz képest
Mit csinál Theratechnologies?
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
ipo év -hoz hasonló cégek Theratechnologies
- Xiana Mining nak IPO év 2008 van
- Bassari Resources nak IPO év 2008 van
- ITV Plc nak IPO év 2008 van
- Calfrac Well Services nak IPO év 2008 van
- Consolidated Tin Mines nak IPO év 2008 van
- Ocean Agro (India) nak IPO év 2008 van
- Theratechnologies nak IPO év 2009 van
- Wow Unlimited Media nak IPO év 2010 van
- Generac Inc nak IPO év 2010 van
- Standard AVB nak IPO év 2010 van
- AB Science S.A nak IPO év 2010 van
- Hudson Pacific Properties Inc nak IPO év 2010 van
- Cencora nak IPO év 2010 van